|
Left Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Interaction of BMP10 with Tcap may modulate the course of hypertensive cardiac hypertrophy.
|
17921333 |
2007 |
|
Tetralogy of Fallot
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mechanism study revealed that BMP10 suppressed tumor cell growth by inhibiting STAT3 signaling.
|
31417183 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Altogether, our data show that in a tumor environment BMP9 and BMP10 play different roles and thus blocking their shared receptor ALK1 is maybe not appropriate.
|
30165893 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
This would suggest a potential tumour suppressor role of BMP10 in bladder cancer.
|
23645739 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein-10 (BMP-10) may function as a tumor suppressor in breast cancer.
|
20608934 |
2010 |
|
Hypertensive disease
|
0.030 |
Biomarker
|
group |
BEFREE |
In agreement with these observations, we found that the BMP9/BMP10 ligand trap ALK1<sub>ECD</sub> administered in monocrotaline or Sugen/hypoxia (SuHx) rats substantially attenuate proliferation of pulmonary vascular cells, inflammatory cell infiltration, and regresses established pulmonary hypertension in rats.
|
30636542 |
2019 |
|
Hypertensive disease
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In adults, BMP10 expression is restricted to the right atrium, though ventricular hypertrophy is accompanied by increased BMP10 expression in a rat hypertension model.
|
26631724 |
2016 |
|
Hypertensive disease
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These observations suggested that hypertension induced expression of prohypertrophic BMP10, and the hypertrophic effect of BMP10 was modulated, at least in part, by its binding to Tcap at the Z disc.
|
17921333 |
2007 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The expression of bone morphogenetic protein-10 (BMP-10) is downregulated in some cancer types, but its function and mechanism in ovarian cancer remains unclear.
|
30401582 |
2019 |
|
Hirschsprung Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Dysregulation of BMP10 has been observed in several diseases, including hypertensive cardiac hypertrophy, Hirschsprung disease and blood vessel formation.
|
31417183 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
BMP-10 overexpression or knockdown significantly inhibited or promoted proliferation, migration, and invasion of ovarian cancer cells, respectively.
|
30401582 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The expression of bone morphogenetic protein-10 (BMP-10) is downregulated in some cancer types, but its function and mechanism in ovarian cancer remains unclear.
|
30401582 |
2019 |
|
Hirschsprung Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
BMP2, BMP5 and BMP10 are elevated in the stenotic colon segment of HSCR, and BMPs signaling plays a pivotal role in the development of HSCR.
|
24551273 |
2014 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bone morphogenetic protein-10 (BMP10), a novel member of the bone morphogenetic protein (BMP) family, has been indicated as a possible tumour suppressor in prostate and breast cancer.
|
23645739 |
2013 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bone morphogenetic protein-10 (BMP10), a novel member of the bone morphogenetic protein (BMP) family, has been indicated as a possible tumour suppressor in prostate and breast cancer.
|
23645739 |
2013 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining and quantitative real-time PCR revealed a decreased expression of BMP-10 in breast cancer.
|
20608934 |
2010 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The expression of BMP-10 was examined in a cohort of human breast cancer specimens (normal, n = 23; cancer, n = 97), using both quantitative real-time PCR and immunohistochemical staining.
|
20608934 |
2010 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining and quantitative real-time PCR revealed a decreased expression of BMP-10 in breast cancer.
|
20608934 |
2010 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The effect on growth, cell matrix adhesion, motility, and invasion of MDA-MB-231 cells by BMP-10 was then investigated using in vitro growth assays.
|
20608934 |
2010 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The expression of BMP-10 was examined in a cohort of human breast cancer specimens (normal, n = 23; cancer, n = 97), using both quantitative real-time PCR and immunohistochemical staining.
|
20608934 |
2010 |
|
Pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.
|
31661308 |
2020 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Plasma BMP9 and BMP10 levels and activity were assayed in PAH patients with GDF2 mutations, and controls.
|
31661308 |
2020 |
|
Refractory anemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The hyperplastic trabeculae result from enhanced proliferation of trabecular cardiomyocyte (CMs), which is associated with upregulation of Bmp10, increased retinoic acid (RA) signaling, and Erk1/2 hyperphosphorylation in the myocardium.
|
31112136 |
2019 |
|
Congenital arteriovenous malformation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our findings support a unique role for Bmp10 as a non-redundant Alk1 ligand required to maintain the post-embryonic vasculature and establish zebrafish bmp10 mutants as a model for AVM-associated high-output heart failure, which is an increasingly recognized complication of severe liver involvement in HHT2.
|
31828546 |
2019 |